CRMD | CorMedix Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	8.99 - 9.26
52 Week Range	3.61 - 13.85
Beta	1.60
Implied Volatility	80.05%
IV Rank	47.90%
Day's Volume	1,127,051
Average Volume	1,417,729
Shares Outstanding	65,181,799
Market Cap	599,020,733
Sector	Healthcare
Industry	Biotechnology
IPO Date	2010-05-13

Valuation
Profitability
Growth
Health
P/E Ratio	-30.63
Forward P/E Ratio	-4.34
EPS	-0.30
1YR Price Target	14.00
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	82
Country	USA
Website	CRMD

Cormedix Inc is a biopharmaceutical company that focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. It has been in-licensed to develop and commercialize Neutrolin, which is a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings such as hemodialysis, total parenteral nutrition, and oncology. The Neutrolin product is designed to target unmet medical needs.

CRMD's peers: TARS, LIAN, ALDX, TVTX, ETON, PGEN, TCRR, SGMO, APTO, ELYM, INBX, MACK, CELC, ELVN, REPL, NVCT, LYRA, KRON, GOSS, CNTB, ABOS, NUVB, ELDN

*Chart delayed

Analyzing fundamentals for CRMD we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is very bad and Health is very weak. For more detailed analysis please see CRMD Fundamentals page.

Watching at CRMD technicals we can see that long-term trend is bullish, while middle-term trend is bearish, as well as bearish short-term trend. More technicals details can be found on CRMD Technicals page.